SINOMED(SH:688108) Xin Lang Cai Jing·2025-09-08 10:14Core Viewpoint - The company has addressed recent false information circulating on various media platforms, confirming that these claims do not reflect the actual situation of the company [1] Group 1: Company Response to Misinformation - The company has acknowledged the spread of false information regarding administrative regulatory measures and financial issues, which has led to significant stock price fluctuations [1] - The company is committed to combating and preventing the spread of such misinformation to maintain a stable market environment [1] - Legal actions will be taken against the sources of false information and malicious reports to protect the interests of investors [1] Group 2: Product Development and Regulatory Status - The company is in the process of submitting CE certification applications for three neuro-interventional products, which are expected to be submitted in the second half of 2024 and the first half of 2025 [1] - There are currently no indications that these applications will be denied or fail to pass [1] Group 3: Acquisition and Operational Status - The company completed the acquisition of eLum, a neuro-interventional subsidiary, in early 2024, which focuses on the research, development, and production of neuro-interventional medical devices [1] - Following the acquisition, the company has been integrating technology and talent between the parent and subsidiary companies, and eLum is operating normally without any external factors affecting its business operations [1]